Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0.

التفاصيل البيبلوغرافية
العنوان:	Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0.
المؤلفون:	Albert NL; Department of Nuclear Medicine, LMU Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. nathalie.albert@med.uni-muenchen.de., Preusser M; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria., Traub-Weidinger T; Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.; Department of Diagnostic and Therapeutic Nuclear Medicine, Clinic Donaustadt, Vienna Health Care Group, Vienna, Austria., Tolboom N; Princess Máxima Centre for Paediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, Netherlands.; Division Imaging & Oncology, University Medical Centre Utrecht, Utrecht, Netherlands., Law I; Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Palmer JD; Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Guedj E; Institut Fresnel, Nuclear Medicine Department, APHM, CNRS, Timone Hospital, CERIMED, Aix Marseille Univ, Marseille, France., Furtner J; Research Center for Medical Image Analysis and Artificial Intelligence (MIAAI), Faculty of Medicine and Dentistry, Danube Private University, 3500, Krems, Austria., Fraioli F; Institute of Nuclear Medicine, University College London (UCL), London, UK., Huang RY; Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA., Johnson DR; Department of Radiology, Mayo Clinic, Rochester, MN, USA., Deroose CM; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, University Hospitals Leuven, KU Leuven, Leuven, Belgium., Herrmann K; Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK) - University Hospital Essen, Essen, Germany., Vogelbaum M; Department of Neurosurgery, Cleveland Clinic, Cleveland, OH, USA., Chang S; Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA, USA., Tonn JC; Department of Neurosurgery, Ludwig-Maximilians-University Munich, Munich, Germany., Weller M; Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland., Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., van den Bent MJ; Department of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands., Verger A; Department of Nuclear Medicine and Nancyclotep Imaging Platform, CHRU Nancy and IADI INSERM UMR 1254, Université de Lorraine, Nancy, France., Ivanidze J; Department of Radiology, Weill Cornell Medicine, New York, NY, USA., Galldiks N; Institute of Neuroscience and Medicine (INM-3), Research Center Juelich, Juelich, Germany.; Department of Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.; Center for Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Cologne, Germany.
المصدر:	European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2024 Jun 20. Date of Electronic Publication: 2024 Jun 20.
Publication Model:	Ahead of Print
نوع المنشور:	Journal Article
اللغة:	English
بيانات الدورية:	Publisher: Springer-Verlag Berlin Country of Publication: Germany NLM ID: 101140988 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1619-7089 (Electronic) Linking ISSN: 16197070 NLM ISO Abbreviation: Eur J Nucl Med Mol Imaging Subsets: MEDLINE
أسماء مطبوعة:	Original Publication: Berlin : Springer-Verlag Berlin, 2002-
مستخلص:	Purpose: To provide practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor (SSTR) ligands. Methods: This joint practice guideline/procedure standard was collaboratively developed by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the PET task force of the Response Assessment in Neurooncology Working Group (PET/RANO). Results: Positron emission tomography (PET) using somatostatin receptor (SSTR) ligands can detect meningioma tissue with high sensitivity and specificity and may provide clinically relevant information beyond that obtained from structural magnetic resonance imaging (MRI) or computed tomography (CT) imaging alone. SSTR-directed PET imaging can be particularly useful for differential diagnosis, delineation of meningioma extent, detection of osseous involvement, and the differentiation between posttherapeutic scar tissue and tumour recurrence. Moreover, SSTR-peptide receptor radionuclide therapy (PRRT) is an emerging investigational treatment approach for meningioma. Conclusion: These practice guidelines will define procedure standards for the application of PET imaging in patients with meningiomas and related SSTR-targeted PRRTs in routine practice and clinical trials and will help to harmonize data acquisition and interpretation across centers, facilitate comparability of studies, and to collect larger databases. The current document provides additional information to the evidence-based recommendations from the PET/RANO Working Group regarding the utilization of PET imaging in meningiomas Galldiks (Neuro Oncol. 2017;19(12):1576-87). The information provided should be considered in the context of local conditions and regulations. (© 2024. The Author(s).)
References:	Dutour A, Kumar U, Panetta R, Ouafik L, Fina F, Sasi R, et al. Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer. 1998;76:620–7. https://doi.org/10.1002/(sici)1097-0215(19980529)76:5%3c620::aid-ijc2%3e3.0.co;2-s . (PMID: 10.1002/(sici)1097-0215(19980529)76:5<620::aid-ijc2>3.0.co;2-s9610716) Wangler C, Beyer L, Bartenstein P, Wangler B, Schirrmacher R, Lindner S. Favorable SSTR subtype selectivity of SiTATE: new momentum for clinical [(18)F]SiTATE PET. EJNMMI Radiopharm Chem. 2022;7:22. https://doi.org/10.1186/s41181-022-00176-x . (PMID: 10.1186/s41181-022-00176-x360649879445141) Wang S, Yang W, Deng J, Zhang J, Ma F, Wang J. Correlation between 99mTc-HYNIC-octreotide SPECT/CT somatostatin receptor scintigraphy and pathological grading of meningioma. J Neurooncol. 2013;113:519–26. https://doi.org/10.1007/s11060-013-1146-y . (PMID: 10.1007/s11060-013-1146-y23657621) Hope TA, Abbott A, Colucci K, Bushnell DL, Gardner L, Graham WS, et al. NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE. J Nucl Med. 2019;60:937–43. https://doi.org/10.2967/jnumed.118.230607 . (PMID: 10.2967/jnumed.118.23060731263080) Afshar-Oromieh A, Wolf MB, Kratochwil C, Giesel FL, Combs SE, Dimitrakopoulou-Strauss A, et al. Comparison of (6)(8)Ga-DOTATOC-PET/CT and PET/MRI hybrid systems in patients with cranial meningioma: Initial results. Neuro Oncol. 2015;17:312–9. https://doi.org/10.1093/neuonc/nou131 . (PMID: 10.1093/neuonc/nou13125008094) Rachinger W, Stoecklein VM, Terpolilli NA, Haug AR, Ertl L, Poschl J, et al. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. J Nucl Med. 2015;56:347–53. https://doi.org/10.2967/jnumed.114.149120 . (PMID: 10.2967/jnumed.114.14912025635133) Graef J, Furth C, Kluge AK, Acker G, Kord M, Zimmermann Z, et al. 68Ga-DOTATOC-PET/MRI-A Secure One-Stop Shop Imaging Tool for Robotic Radiosurgery Treatment Planning in Patients with Optic Nerve Sheath Meningioma. Cancers (Basel). 2021;13. https://doi.org/10.3390/cancers13133305 . Einhellig HC, Siebert E, Bauknecht HC, Tietze A, Graef J, Furth C, et al. Comparison of diagnostic value of 68 Ga-DOTATOC PET/MRI and standalone MRI for the detection of intracranial meningiomas. Sci Rep. 2021;11:9064. https://doi.org/10.1038/s41598-021-87866-9 . (PMID: 10.1038/s41598-021-87866-9339072048079685) Unterrainer M, Kunte SC, Unterrainer LM, Holzgreve A, Delker A, Lindner S, et al. Next-generation PET/CT imaging in meningioma-first clinical experiences using the novel SSTR-targeting peptide [(18)F]SiTATE. Eur J Nucl Med Mol Imaging. 2023. https://doi.org/10.1007/s00259-023-06315-z . (PMID: 10.1007/s00259-023-06315-z3764270710611856) Kunz WG, Jungblut LM, Kazmierczak PM, Vettermann FJ, Bollenbacher A, Tonn JC, et al. Improved detection of transosseous meningiomas using (68)Ga-DOTATATE PET/CT compared with contrast-enhanced MRI. J Nucl Med. 2017;58:1580–7. https://doi.org/10.2967/jnumed.117.191932 . (PMID: 10.2967/jnumed.117.19193228450556) Mahase SS, Roth O’Brien DA, No D, Roytman M, Skafida ME, Lin E, et al. [(68)Ga]-DOTATATE PET/MRI as an adjunct imaging modality for radiation treatment planning of meningiomas. Neurooncol Adv. 2021;3:vdab012. https://doi.org/10.1093/noajnl/vdab012 . (PMID: 10.1093/noajnl/vdab012337384467954102) Milker-Zabel S, Zabel-du Bois A, Henze M, Huber P, Schulz-Ertner D, Hoess A, et al. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys. 2006;65:222–7. https://doi.org/10.1016/j.ijrobp.2005.12.006 . (PMID: 10.1016/j.ijrobp.2005.12.00616488553) Perlow HK, Siedow M, Gokun Y, McElroy J, Matsui J, Zoller W, et al. (68)Ga-DOTATATE PET-Based Radiation Contouring Creates More Precise Radiation Volumes for Patients With Meningioma. Int J Radiat Oncol Biol Phys. 2022;113:859–65. https://doi.org/10.1016/j.ijrobp.2022.04.009 . (PMID: 10.1016/j.ijrobp.2022.04.00935460804) Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376:125–35. https://doi.org/10.1056/NEJMoa1607427 . (PMID: 10.1056/NEJMoa1607427280767095895095) Mirian C, Duun-Henriksen AK, Maier A, Pedersen MM, Jensen LR, Bashir A, et al. Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory Meningioma: Individual patient data meta-analysis. J Nucl Med. 2021;62:507–13. https://doi.org/10.2967/jnumed.120.249607 . (PMID: 10.2967/jnumed.120.24960732859705) Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2019;46:540–57. https://doi.org/10.1007/s00259-018-4207-9 . (PMID: 10.1007/s00259-018-4207-930519867) Zaknun JJ, Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Horsch D, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800–16. https://doi.org/10.1007/s00259-012-2330-6 . (PMID: 10.1007/s00259-012-2330-6233894273622744) Hope TA, Bodei L, Chan JA, El-Haddad G, Fidelman N, Kunz PL, et al. NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of (177)Lu-DOTATATE Peptide Receptor Radionuclide Therapy. J Nucl Med. 2020;61:222–7. https://doi.org/10.2967/jnumed.119.240911 . (PMID: 10.2967/jnumed.119.240911320151649364765) Klingenstein A, Haug AR, Miller C, Hintschich C. Ga-68-DOTA-TATE PET/CT for discrimination of tumors of the optic pathway. Orbit. 2015;34:16–22. https://doi.org/10.3109/01676830.2014.959185 . (PMID: 10.3109/01676830.2014.95918525264824) Afshar-Oromieh A, Giesel FL, Linhart HG, Haberkorn U, Haufe S, Combs SE, et al. Detection of cranial meningiomas: comparison of (6)(8)Ga-DOTATOC PET/CT and contrast-enhanced MRI. Eur J Nucl Med Mol Imaging. 2012;39:1409–15. https://doi.org/10.1007/s00259-012-2155-3 . (PMID: 10.1007/s00259-012-2155-322669255) Unterrainer M, Ruf V, Ilhan H, Vettermann FJ, Cyran CC, Niyazi M, et al. 68Ga-DOTATOC PET/CT Differentiates Meningioma From Dural Metastases. Clin Nucl Med. 2019;44:412–3. https://doi.org/10.1097/RLU.0000000000002513 . (PMID: 10.1097/RLU.000000000000251330829858) Kunz WG, Jungblut LM, Kazmierczak PM, Vettermann FJ, Bollenbacher A, Tonn JC, et al. Improved Detection of Transosseous Meningiomas Using 68Ga-DOTATATE PET-CT Compared to Contrast-Enhanced MRI. J Nucl Med. 2017. https://doi.org/10.2967/jnumed.117.191932 . Nyuyki F, Plotkin M, Graf R, Michel R, Steffen I, Denecke T, et al. Potential impact of (68)Ga-DOTATOC PET/CT on stereotactic radiotherapy planning of meningiomas. Eur J Nucl Med Mol Imaging. 2010;37:310–8. https://doi.org/10.1007/s00259-009-1270-2 . (PMID: 10.1007/s00259-009-1270-219763565) Gehler B, Paulsen F, Oksuz MO, Hauser TK, Eschmann SM, Bares R, et al. [68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning. Radiat Oncol. 2009;4:56. https://doi.org/10.1186/1748-717X-4-56 . (PMID: 10.1186/1748-717X-4-56199226422785827) Graf R, Nyuyki F, Steffen IG, Michel R, Fahdt D, Wust P, et al. Contribution of 68Ga-DOTATOC PET/CT to target volume delineation of skull base meningiomas treated with stereotactic radiation therapy. Int J Radiat Oncol Biol Phys. 2013;85:68–73. https://doi.org/10.1016/j.ijrobp.2012.03.021 . (PMID: 10.1016/j.ijrobp.2012.03.02122575489) Kowalski ES, Khairnar R, Gryaznov AA, Kesari V, Koroulakis A, Raghavan P, et al. (68)Ga-DOTATATE PET-CT as a tool for radiation planning and evaluating treatment responses in the clinical management of meningiomas. Radiat Oncol. 2021;16:151. https://doi.org/10.1186/s13014-021-01875-6 . (PMID: 10.1186/s13014-021-01875-6343998058365988) Ghomari CF, Bender L, Lhermitte B, Noel G, Namer IJ, Bund C. 68Ga-DOTATOC PET in Extracranial Hepatic and Bone Metastasis of Atypical Refractory Meningioma: A Case Report. Clin Nucl Med. 2023;48:176–8. https://doi.org/10.1097/RLU.0000000000004518 . (PMID: 10.1097/RLU.000000000000451836607366) Bashir A, Larsen VA, Ziebell M, Fugleholm K, Law I. Improved Detection of Postoperative Residual Meningioma with [(68)Ga]Ga-DOTA-TOC PET Imaging Using a High-resolution Research Tomograph PET Scanner. Clin Cancer Res. 2021;27:2216–25. https://doi.org/10.1158/1078-0432.CCR-20-3362 . (PMID: 10.1158/1078-0432.CCR-20-336233526423) Ueberschaer M, Vettermann FJ, Forbrig R, Unterrainer M, Siller S, Biczok AM, et al. Simpson Grade Revisited - Intraoperative Estimation of the Extent of Resection in Meningiomas Versus Postoperative Somatostatin Receptor Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging. Neurosurgery. 2020;88:140–6. https://doi.org/10.1093/neuros/nyaa333 . (PMID: 10.1093/neuros/nyaa33332827256) Seystahl K, Stoecklein V, Schuller U, Rushing E, Nicolas G, Schafer N, et al. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake. Neuro Oncol. 2016;18:1538–47. https://doi.org/10.1093/neuonc/now060 . (PMID: 10.1093/neuonc/now060271064045063513) Bashir A, Vestergaard MB, Binderup T, Broholm H, Marner L, Ziebell M, et al. Pharmacokinetic analysis of [(68)Ga]Ga-DOTA-TOC PET in meningiomas for assessment of in vivo somatostatin receptor subtype 2. Eur J Nucl Med Mol Imaging. 2020;47:2577–88. https://doi.org/10.1007/s00259-020-04759-1 . (PMID: 10.1007/s00259-020-04759-132170347) Galldiks N, Albert NL, Sommerauer M, Grosu AL, Ganswindt U, Law I, et al. PET Imaging in patients with Meningioma - Report of the RANO/PET Group. Neuro Oncol. 2017;19(12):1576–87. https://doi.org/10.1093/neuonc/nox112 . (PMID: 10.1093/neuonc/nox112286055325716194) Goldbrunner R, Stavrinou P, Jenkinson MD, Sahm F, Mawrin C, Weber DC, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021;23:1821–34. https://doi.org/10.1093/neuonc/noab150 . (PMID: 10.1093/neuonc/noab150341817338563316) Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging. 2017;44:1588–601. https://doi.org/10.1007/s00259-017-3728-y . (PMID: 10.1007/s00259-017-3728-y28547177) Ilhan H, Lindner S, Todica A, Cyran CC, Tiling R, Auernhammer CJ, et al. Biodistribution and first clinical results of (18)F-SiFAlin-TATE PET: a novel (18)F-labeled somatostatin analog for imaging of neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2020;47:870–80. https://doi.org/10.1007/s00259-019-04501-6 . (PMID: 10.1007/s00259-019-04501-631492994) Unterrainer M, Lindner S, Beyer L, Gildehaus FJ, Todica A, Mittlmeier LM, et al. PET Imaging of Meningioma Using the Novel SSTR-Targeting Peptide 18F-SiTATE. Clin Nucl Med. 2021;46:667–8. https://doi.org/10.1097/RLU.0000000000003607 . (PMID: 10.1097/RLU.000000000000360733782306) Rodriguez J, Martinez G, Mahase S, Roytman M, Haghdel A, Kim S, et al. Cost-Effectiveness Analysis of (68)Ga-DOTATATE PET/MRI in Radiotherapy Planning in Patients with Intermediate-Risk Meningioma. AJNR Am J Neuroradiol. 2023. https://doi.org/10.3174/ajnr.A7901 . (PMID: 10.3174/ajnr.A79013729081810187821) Gillings N, Hjelstuen O, Behe M, Decristoforo C, Elsinga PH, Ferrari V, et al. EANM guideline on quality risk management for radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2022;49:3353–64. https://doi.org/10.1007/s00259-022-05738-4 . (PMID: 10.1007/s00259-022-05738-4353859869308578) Hendrikse H, Kiss O, Kunikowska J, Wadsak W, Decristoforo C, Patt M. EANM position on the in-house preparation of radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2022;49:1095–8. https://doi.org/10.1007/s00259-022-05694-z . (PMID: 10.1007/s00259-022-05694-z35050391) Treves ST, Gelfand MJ, Fahey FH, Parisi MT. 2016 Update of the North American Consensus Guidelines for Pediatric Administered Radiopharmaceutical Activities. J Nucl Med. 2016;57:15N-N18. (PMID: 27909182) Unterrainer M, Ilhan H, Vettermann F, Cyran CC, Tonn JC, Niyazi M, et al. Whole-Body Staging of Metastatic Atypical Meningioma Using 68Ga-DOTATATE PET/CT. Clin Nucl Med. 2019;44:227–8. https://doi.org/10.1097/RLU.0000000000002422 . (PMID: 10.1097/RLU.000000000000242230589668) Ivanidze J, Roytman M, Skafida M, Kim S, Glynn S, Osborne JR, et al. Dynamic (68)Ga-DOTATATE PET/MRI in the Diagnosis and Management of Intracranial Meningiomas. Radiol Imaging Cancer. 2022;4:e210067. https://doi.org/10.1148/rycan.210067 . (PMID: 10.1148/rycan.210067352750198965533) Andersen FL, Ladefoged CN, Beyer T, Keller SH, Hansen AE, Hojgaard L, et al. Combined PET/MR imaging in neurology: MR-based attenuation correction implies a strong spatial bias when ignoring bone. Neuroimage. 2014;84:206–16. https://doi.org/10.1016/j.neuroimage.2013.08.042 . (PMID: 10.1016/j.neuroimage.2013.08.04223994317) Bailey DL, Pichler BJ, Guckel B, Antoch G, Barthel H, Bhujwalla ZM, et al. Combined PET/MRI: Global Warming-Summary Report of the 6th International Workshop on PET/MRI, March 27–29, 2017, Tubingen, Germany. Mol Imaging Biol. 2018;20:4–20. https://doi.org/10.1007/s11307-017-1123-5 . (PMID: 10.1007/s11307-017-1123-528971346) Koesters T, Friedman KP, Fenchel M, Zhan Y, Hermosillo G, Babb J, et al. Dixon sequence with superimposed model-based bone compartment provides highly accurate PET/MR attenuation correction of the brain. J Nucl Med. 2016;57:918–24. https://doi.org/10.2967/jnumed.115.166967 . (PMID: 10.2967/jnumed.115.16696726837338) Ladefoged CN, Andersen FL, Kjaer A, Hojgaard L, Law I. RESOLUTE PET/MRI Attenuation Correction for O-(2-(18)F-fluoroethyl)-L-tyrosine (FET) in Brain Tumor Patients with Metal Implants. Front Neurosci. 2017;11:453. https://doi.org/10.3389/fnins.2017.00453 . (PMID: 10.3389/fnins.2017.00453288483795554515) Ladefoged CN, Law I, Anazodo U, St Lawrence K, Izquierdo-Garcia D, Catana C, et al. A multi-centre evaluation of eleven clinically feasible brain PET/MRI attenuation correction techniques using a large cohort of patients. Neuroimage. 2017;147:346–59. https://doi.org/10.1016/j.neuroimage.2016.12.010 . (PMID: 10.1016/j.neuroimage.2016.12.01027988322) Rausch I, Rischka L, Ladefoged CN, Furtner J, Fenchel M, Hahn A, et al. PET/MRI for oncologic brain imaging: A comparison of standard mr-based attenuation corrections with a model-based approach for the siemens mMR PET/MR system. J Nucl Med. 2017;58:1519–25. https://doi.org/10.2967/jnumed.116.186148 . (PMID: 10.2967/jnumed.116.18614828254872) Ladefoged CN, Hansen AE, Keller SH, Holm S, Law I, Beyer T, et al. Impact of incorrect tissue classification in Dixon-based MR-AC: fat-water tissue inversion. EJNMMI Phys. 2014;1:101. https://doi.org/10.1186/s40658-014-0101-0 . (PMID: 10.1186/s40658-014-0101-0265014594545462) Ladefoged CN, Hansen AE, Keller SH, Fischer BM, Rasmussen JH, Law I, et al. Dental artifacts in the head and neck region: implications for Dixon-based attenuation correction in PET/MR. EJNMMI Phys. 2015;2:8. https://doi.org/10.1186/s40658-015-0112-5 . (PMID: 10.1186/s40658-015-0112-5265018104546019) Brendle C, Schmidt H, Oergel A, Bezrukov I, Mueller M, Schraml C, et al. Segmentation-based attenuation correction in positron emission tomography/magnetic resonance: erroneous tissue identification and its impact on positron emission tomography interpretation. Invest Radiol. 2015;50:339–46. https://doi.org/10.1097/RLI.0000000000000131 . (PMID: 10.1097/RLI.000000000000013125585210) Ter Voert E, Veit-Haibach P, Ahn S, Wiesinger F, Khalighi MM, Levin CS, et al. Clinical evaluation of TOF versus non-TOF on PET artifacts in simultaneous PET/MR: a dual centre experience. Eur J Nucl Med Mol Imaging. 2017;44:1223–33. https://doi.org/10.1007/s00259-017-3619-2 . (PMID: 10.1007/s00259-017-3619-228124091) Rezaei A, Schramm G, Willekens SMA, Delso G, Van Laere K, Nuyts J. A Quantitative Evaluation of Joint Activity and Attenuation Reconstruction in TOF PET/MR Brain Imaging. J Nucl Med. 2019;60:1649–55. https://doi.org/10.2967/jnumed.118.220871 . (PMID: 10.2967/jnumed.118.220871309798236836858) Munk OL, Tolbod LP, Hansen SB, Bogsrud TV. Point-spread function reconstructed PET images of sub-centimeter lesions are not quantitative. EJNMMI Phys. 2017;4:5. https://doi.org/10.1186/s40658-016-0169-9 . (PMID: 10.1186/s40658-016-0169-9280919575236043) Aide N, Lasnon C, Veit-Haibach P, Sera T, Sattler B, Boellaard R. EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies. Eur J Nucl Med Mol Imaging. 2017;44:17–31. https://doi.org/10.1007/s00259-017-3740-2 . (PMID: 10.1007/s00259-017-3740-2286233765541084) Minoshima S, Koeppe RA, Mintun MA, Berger KL, Taylor SF, Frey KA, et al. Automated detection of the intercommissural line for stereotactic localization of functional brain images. J Nucl Med. 1993;34:322–9. (PMID: 8429356) Ivanidze J, Roytman M, Lin E, Magge RS, Pisapia DJ, Liechty B, et al. Gallium-68 DOTATATE PET in the Evaluation of Intracranial Meningiomas. J Neuroimaging. 2019;29:650–6. https://doi.org/10.1111/jon.12632 . (PMID: 10.1111/jon.1263231107591) Kim SH, Roytman M, Madera G, Magge RS, Liechty B, Ramakrishna R, et al. Evaluating diagnostic accuracy and determining optimal diagnostic thresholds of different approaches to [(68)Ga]-DOTATATE PET/MRI analysis in patients with meningioma. Sci Rep. 2022;12:9256. https://doi.org/10.1038/s41598-022-13467-9 . (PMID: 10.1038/s41598-022-13467-9356618099166786) Boursier C, Zaragori T, Bros M, Bordonne M, Melki S, Taillandier L, et al. Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy. Eur Radiol. 2023. https://doi.org/10.1007/s00330-023-09697-8 . (PMID: 10.1007/s00330-023-09697-837402003) Marincek N, Radojewski P, Dumont RA, Brunner P, Muller-Brand J, Maecke HR, et al. Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial. J Nucl Med. 2015;56:171–6. https://doi.org/10.2967/jnumed.114.147256 . (PMID: 10.2967/jnumed.114.14725625593116) Gerster-Gillieron K, Forrer F, Maecke H, Mueller-Brand J, Merlo A, Cordier D. 90Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas. J Nucl Med. 2015;56:1748–51. https://doi.org/10.2967/jnumed.115.155853 . (PMID: 10.2967/jnumed.115.15585326294303) Kriwanek F, Ulbrich L, Lechner W, Lutgendorf-Caucig C, Konrad S, Waldstein C, et al. Impact of SSTR PET on Inter-Observer Variability of Target Delineation of Meningioma and the Possibility of Using Threshold-Based Segmentations in Radiation Oncology. Cancers (Basel). 2022;14. https://doi.org/10.3390/cancers14184435 . Roytman M, Pisapia DJ, Liechty B, Lin E, Skafida M, Magge RS, et al. Somatostatin receptor-2 negative meningioma: pathologic correlation and imaging implications. Clin Imaging. 2020;66:18–22. https://doi.org/10.1016/j.clinimag.2020.04.026 . (PMID: 10.1016/j.clinimag.2020.04.02632442855) Unterrainer M, Ilhan H, Todica A, Bartenstein P, Albert NL. Epidural Metastases From Follicular Thyroid Cancer Mimicking Meningiomas in 68Ga-DOTATATE PET. Clin Nucl Med. 2017;42:805–6. https://doi.org/10.1097/RLU.0000000000001793 . (PMID: 10.1097/RLU.000000000000179328806249) Bashir A, Broholm H, Clasen-Linde E, Vestergaard MB, Law I. Pearls and Pitfalls in Interpretation of 68Ga-DOTATOC PET Imaging. Clin Nucl Med. 2020;45:e279–80. https://doi.org/10.1097/RLU.0000000000003012 . (PMID: 10.1097/RLU.000000000000301232332303) Unterrainer M, Ruf V, Ilhan H, Vettermann F, Holzgreve A, Cyran CC, et al. Teaching NeuroImages: Advanced imaging of neurosarcoidosis with (68)Ga-DOTATATE PET/CT. Neurology. 2019;92:e2512–3. https://doi.org/10.1212/WNL.0000000000007544 . (PMID: 10.1212/WNL.000000000000754431110154) Huang RY, Bi WL, Weller M, Kaley T, Blakeley J, Dunn I, et al. Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. Neuro Oncol. 2019;21:26–36. https://doi.org/10.1093/neuonc/noy137 . (PMID: 10.1093/neuonc/noy13730137421) Huang RY, Bi WL, Griffith B, Kaufmann TJ, la Fougere C, Schmidt NO, et al. Imaging and diagnostic advances for intracranial meningiomas. Neuro Oncol. 2019;21:i44–61. https://doi.org/10.1093/neuonc/noy143 . (PMID: 10.1093/neuonc/noy143306494916347083) Albert NL, Galldiks N, Ellingson BM, van den Bent MJ, Chang SM, Cicone F, et al. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group. Lancet Oncol. 2024;25:e29–41. https://doi.org/10.1016/S1470-2045(23)00525-9 . (PMID: 10.1016/S1470-2045(23)00525-938181810) Kurz SC, Zan E, Cordova C, Troxel AB, Barbaro M, Silverman JS, et al. Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma. Clin Cancer Res. 2024;30:680–6. https://doi.org/10.1158/1078-0432.CCR-23-2533 . (PMID: 10.1158/1078-0432.CCR-23-253338048045) Kim SH, Chang SJC, Dobri G, Strauss S, Lin E, Zavaletta V, et al. [68 Ga]-DOTATATE PET/MR-based evaluation of physiologic somatostatin receptor 2 expression in the adult pituitary gland as a function of age and sex in a prospective cohort. Pituitary. 2023;26:419–28. https://doi.org/10.1007/s11102-023-01329-0 . (PMID: 10.1007/s11102-023-01329-037285059) Kiviniemi A, Gardberg M, Frantzen J, Pesola M, Vuorinen V, Parkkola R, et al. Somatostatin receptor subtype 2 in high-grade gliomas: PET/CT with (68)Ga-DOTA-peptides, correlation to prognostic markers, and implications for targeted radiotherapy. EJNMMI Res. 2015;5:25. https://doi.org/10.1186/s13550-015-0106-2 . (PMID: 10.1186/s13550-015-0106-2259778824420768) van der Hoek J, Waaijers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, et al. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab. 2005;289:E278–87. https://doi.org/10.1152/ajpendo.00004.2005 . (PMID: 10.1152/ajpendo.00004.200515769796) Vonken EPA, Bruijnen RCG, Snijders TJ, Seute T, Lam M, Keizer B, et al. Intraarterial Administration Boosts (177)Lu-HA-DOTATATE Accumulation in Salvage Meningioma Patients. J Nucl Med. 2022;63:406–9. https://doi.org/10.2967/jnumed.121.262491 . (PMID: 10.2967/jnumed.121.262491343017838978193) Kreissl MC, Hanscheid H, Lohr M, Verburg FA, Schiller M, Lassmann M, et al. Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Radiat Oncol. 2012;7:99. https://doi.org/10.1186/1748-717X-7-99 . (PMID: 10.1186/1748-717X-7-99227209023439242) Hartrampf PE, Hanscheid H, Kertels O, Schirbel A, Kreissl MC, Flentje M, et al. Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Clin Transl Radiat Oncol. 2020;22:29–32. https://doi.org/10.1016/j.ctro.2020.03.002 . (PMID: 10.1016/j.ctro.2020.03.002321953777075763) Sjogreen Gleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C, et al. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022;49:1778–809. https://doi.org/10.1007/s00259-022-05727-7 . (PMID: 10.1007/s00259-022-05727-7352849699015994) van der Pol J, Voo S, Bucerius J, Mottaghy FM. Consequences of radiopharmaceutical extravasation and therapeutic interventions: a systematic review. Eur J Nucl Med Mol Imaging. 2017;44:1234–43. https://doi.org/10.1007/s00259-017-3675-7 . (PMID: 10.1007/s00259-017-3675-7283033005434120) Tennvall J, Fischer M, Bischof Delaloye A, Bombardieri E, Bodei L, Giammarile F, et al. EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging. 2007;34:616–22. https://doi.org/10.1007/s00259-007-0372-y . (PMID: 10.1007/s00259-007-0372-y17323056) Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. (177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:1752–63. https://doi.org/10.1016/S1470-2045(21)00572-6 . (PMID: 10.1016/S1470-2045(21)00572-634793718) Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54. https://doi.org/10.1007/s00259-014-2961-x . (PMID: 10.1007/s00259-014-2961-x25452219) Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181–200. https://doi.org/10.1007/s00259-009-1297-4 . (PMID: 10.1007/s00259-009-1297-419915839)
فهرسة مساهمة:	Keywords: DOTATATE; DOTATOC; Meningioma; PET; PRRT; Procedure guideline; SiTATE; Somatostatin receptor; Targeted radionuclide therapy; Theranostics
تواريخ الأحداث:	Date Created: 20240619 Latest Revision: 20240619
رمز التحديث:	20240620
DOI:	10.1007/s00259-024-06783-x
PMID:	38898354
قاعدة البيانات:	MEDLINE

Find this article in full text from Springer Verlag.

Full Text Finder

الوصف
تدمد:	1619-7089
DOI:	10.1007/s00259-024-06783-x